Unichem Laboratories Ltd up by 6.56 percent - Traders Corners | Espresso

EspressoLogy

Espresso Shot of the Day - Unichem Laboratories Ltd up by 6.56 percent

October 31, 2022
Espresso Shot of the Day - Unichem Laboratories Ltd up by 6.56 percent

UNICHEM LABORATORIES LTD 411.75  (+6.56%) BSE – INE351A01035| 31st October 2022

https://www.myespresso.com/images/Espresso%20newsletter%20graph%20image_%20Unichem%20Laboratories%20Ltd.%20310122-202210311825517785639.jpg

Promoted by the late Mr. Amrut Mody, a pioneer of the Indian pharmaceuticals business, Unichem Laboratories has grown to become one of India's most respected pharmaceutical companies. It is committed to deliver better health through superior products. By combining strategic research and in-depth industry knowledge, Unichem aims to transform itself into a global pharmaceutical drug Company with an increasing focus on cutting-edge research and developed markets. With formulations constituting the core of the company’s business, Unichem is integrated backwards with API Manufacturing, which adds value to the customer in terms of quality and sustainability. Inspired by an ambition to drive path-breaking innovative research, Unichem aims to enhance people’s health by consistently providing better, more effective, and safer products.


Recent Drivers

  • Unichem Laboratories said on October 14,2022 that it has received abbreviated new drug application (ANDA) approval for its Extended Phenytoin Sodium capsules from the United States Food and Drug Administration (USFDA). Extended Phenytoin Sodium capsules are used for treating tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery.
  • Unichem Lab received Rs.270 crores for a 19.97% stake sale for the first tranche of selling of Optimus to Sekhmet Pharmaventures Private Limited.
  • On August 23,2022,Unichem Laboratories received ANDA approval for its Carbamazepine Tablets USP, 200 mg from the United States Food and Drug Administration (USFDA) to market a generic version of TEGRETOL (Carbamazepine) Tablet, 200 mg of Novartis Pharmaceuticals Corp
  • On August 16,2022, the United States Food and Drug Administration (USFDA) approved the company’s ask to market a generic version of Seroquel Xr (Quetiapine) tablet and also extended release of Astra Zeneca Pharmaceuticals. The product will be commercialized from Unichem's Goa Plant.
  • On August 10,2022, Unichem Laboratories reported a net Sale of Rs 309.61 crore in June 2022 up 3.93% from Rs. 297.91 crore in June 2021.
  • Board Recommended a dividend of Rs.4/-(200%) per equity share of Rs.2/- each, for the year ended March 31, 2022, subject to approval of shareholders at the ensuing Annual General Meeting. The Ex-date for the same was August 1,2022.


       (Sources: BSE, Money control, Business Standard)


Technical Force*

  • S&P BSE Sensex cap month till date gain by 1.24%.
  • 3 months avg. NSE volume: 1,41,747.
  • Quantity traded: 58,912 | Deliverable quantity: 34,057 (57.81%).
  • Stock price jumped by more than 100 % from a one-year low level: 197.50 (Nov 22, 2021)
  • Daily RSI (14) is near oversold territory today.
  • 52-week-high: 418.15 | 52-week-low: 197.50.


Key Pivot (Yearly)

R4

R3

R2

R1

PP /FIB PP

S1

S2

S3

S4

Pivot Point

-

527.00

450.95

349.60

273.55

172.20

96.15

-

-

Fibonacci Pivot

450.95

383.18

341.32

314.35

273.55

232.75

205.78

163.92

96.15


Today’s Close

411.75

SMA

BSE

10 DAY

390.92

20 DAY

383.01

50 DAY

362.40

200 DAY

286.73


Some Key Ratios (Source: BSE)

Market Cap:  2,898.96 Crores

PE:  -

OPM%: 0.39

ROE%:  -

Promoters holding%: 50.93

Prev. Close:  386.40


https://www.myespresso.com/images/espresso_shot_blog_credit_image%20WD-202206271809546799546.jpg


The scope and usability of this information/data is time-sensitive and market-based, and as such the same may become outdated for the investment decisions of clients, for which Espresso Financial Services Pvt. Ltd bears no responsibility. References to securities do not constitute a recommendation to buy, sell or hold such securities. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document and should consult his own advisors to determine the merits and risks of such an investment. Espresso Financial Services Pvt. Limited is under no obligation to update the information in this document from time-to-time.


Chandresh Khona
by Chandresh Khona

Product Offerings Head

A teacher, writer, travel buff and now Espresso's Product Offerings Head. Ten years here has allowed me to lead the digital team at Sharekhan. My true passion lies in stock market charts.